FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)

View source ↗

Summary

FDA records a supplemental application for ZYCLARA (imiquimod) from Bausch Health US, LLC, filed to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Basal Cell Carcinoma Superficial
• Condyloma Acuminata

Drugs mentioned

• ZYCLARA (Imiquimod)

Snippet

SUPPL AP for ZYCLARA (IMIQUIMOD)